Cargando…

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial

We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from patients with stage IIB-IIIC HER-2-negative BC randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanucci, Kristina A., Bai, Yalai, Pelekanou, Vasiliki, Nahleh, Zeina A., Shafi, Saba, Burela, Sneha, Barlow, William E., Sharma, Priyanka, Thompson, Alastair M., Godwin, Andrew K., Rimm, David L., Hortobagyi, Gabriel N., Liu, Yihan, Wang, Leona, Wei, Wei, Pusztai, Lajos, Blenman, Kim R. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182981/
https://www.ncbi.nlm.nih.gov/pubmed/37179362
http://dx.doi.org/10.1038/s41523-023-00535-0
_version_ 1785041860997152768
author Fanucci, Kristina A.
Bai, Yalai
Pelekanou, Vasiliki
Nahleh, Zeina A.
Shafi, Saba
Burela, Sneha
Barlow, William E.
Sharma, Priyanka
Thompson, Alastair M.
Godwin, Andrew K.
Rimm, David L.
Hortobagyi, Gabriel N.
Liu, Yihan
Wang, Leona
Wei, Wei
Pusztai, Lajos
Blenman, Kim R. M.
author_facet Fanucci, Kristina A.
Bai, Yalai
Pelekanou, Vasiliki
Nahleh, Zeina A.
Shafi, Saba
Burela, Sneha
Barlow, William E.
Sharma, Priyanka
Thompson, Alastair M.
Godwin, Andrew K.
Rimm, David L.
Hortobagyi, Gabriel N.
Liu, Yihan
Wang, Leona
Wei, Wei
Pusztai, Lajos
Blenman, Kim R. M.
author_sort Fanucci, Kristina A.
collection PubMed
description We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from patients with stage IIB-IIIC HER-2-negative BC randomized to neoadjuvant chemotherapy ± bevacizumab. TILs quantification was performed on full sections using QuPath open-source software with a convolutional neural network cell classifier (CNN11). We used easTILs% as a digital metric of TILs score defined as [sum of lymphocytes area (mm(2))/stromal area(mm(2))] × 100. Pathologist-read stromal TILs score (sTILs%) was determined following published guidelines. Mean pretreatment easTILs% was significantly higher in cases with pCR compared to residual disease (median 36.1 vs.14.8%, p < 0.001). We observed a strong positive correlation (r = 0.606, p < 0.0001) between easTILs% and sTILs%. The area under the prediction curve (AUC) was higher for easTILs% than sTILs%, 0.709 and 0.627, respectively. Image analysis-based TILs quantification is predictive of pCR in BC and had better response discrimination than pathologist-read sTILs%.
format Online
Article
Text
id pubmed-10182981
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101829812023-05-15 Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial Fanucci, Kristina A. Bai, Yalai Pelekanou, Vasiliki Nahleh, Zeina A. Shafi, Saba Burela, Sneha Barlow, William E. Sharma, Priyanka Thompson, Alastair M. Godwin, Andrew K. Rimm, David L. Hortobagyi, Gabriel N. Liu, Yihan Wang, Leona Wei, Wei Pusztai, Lajos Blenman, Kim R. M. NPJ Breast Cancer Article We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from patients with stage IIB-IIIC HER-2-negative BC randomized to neoadjuvant chemotherapy ± bevacizumab. TILs quantification was performed on full sections using QuPath open-source software with a convolutional neural network cell classifier (CNN11). We used easTILs% as a digital metric of TILs score defined as [sum of lymphocytes area (mm(2))/stromal area(mm(2))] × 100. Pathologist-read stromal TILs score (sTILs%) was determined following published guidelines. Mean pretreatment easTILs% was significantly higher in cases with pCR compared to residual disease (median 36.1 vs.14.8%, p < 0.001). We observed a strong positive correlation (r = 0.606, p < 0.0001) between easTILs% and sTILs%. The area under the prediction curve (AUC) was higher for easTILs% than sTILs%, 0.709 and 0.627, respectively. Image analysis-based TILs quantification is predictive of pCR in BC and had better response discrimination than pathologist-read sTILs%. Nature Publishing Group UK 2023-05-13 /pmc/articles/PMC10182981/ /pubmed/37179362 http://dx.doi.org/10.1038/s41523-023-00535-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fanucci, Kristina A.
Bai, Yalai
Pelekanou, Vasiliki
Nahleh, Zeina A.
Shafi, Saba
Burela, Sneha
Barlow, William E.
Sharma, Priyanka
Thompson, Alastair M.
Godwin, Andrew K.
Rimm, David L.
Hortobagyi, Gabriel N.
Liu, Yihan
Wang, Leona
Wei, Wei
Pusztai, Lajos
Blenman, Kim R. M.
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
title Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
title_full Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
title_fullStr Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
title_full_unstemmed Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
title_short Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
title_sort image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in swog s0800 neoadjuvant chemotherapy trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182981/
https://www.ncbi.nlm.nih.gov/pubmed/37179362
http://dx.doi.org/10.1038/s41523-023-00535-0
work_keys_str_mv AT fanuccikristinaa imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT baiyalai imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT pelekanouvasiliki imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT nahlehzeinaa imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT shafisaba imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT burelasneha imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT barlowwilliame imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT sharmapriyanka imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT thompsonalastairm imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT godwinandrewk imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT rimmdavidl imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT hortobagyigabrieln imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT liuyihan imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT wangleona imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT weiwei imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT pusztailajos imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial
AT blenmankimrm imageanalysisbasedtumorinfiltratinglymphocytesmeasurementpredictsbreastcancerpathologiccompleteresponseinswogs0800neoadjuvantchemotherapytrial